Clinical trial

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Invitation only · Phase 2 · 2 countries · Registry ID NCT07156578

Invitation onlyPhase 2Interventional

What this study is about

This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age12 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionHypothalamic Obesity

Full registry criteria

Key Inclusion Criteria: * Completed LG-MCCL005 and participant demonstrated adequate safety and tolerability in that study as determined by the Investigator. * Agree to use a highly effective form of contraception and follow contraception requirements throughout the study and for 90 days after. Key Exclusion Criteria: * Willing to remain off of: CYP3A4 inhibitors, strong CYP3A4 inducers, and P-glycoprotein inhibitors or substrates for the duration of the study. * In the opinion of the Investigator, participant is not suitable to participate in the study. Other protocol defined Inclusion/Exclusion criteria may apply.